During the poster session, Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model.
Another study dealing with the effects of obeticholic acid on atherosclerosis and NASH in LDL-r KO mice will be presented by Dr. François Briand, Director of Research and Business Development, during the morning poster session on Tuesday, June the 12th (session# CS 3-10: Type 2 Diabetes: A Persistent Challenge).

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.